Analysis: FDA Advisory Committee Snubs MDMA-Assisted Therapy for PTSD in Overwhelming “No” Vote – Psychedelic Alpha

Instead, now that the dust has begun to settle, I (Josh Hardman) attempt to explore some of the lesser-discussed themes that emerged in the meeting, and aftermath.

Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.


Already a member? Log In


   Regular Bulletins covering key topics and trends in the psychedelics space
   Regular articles and deep dives across psychedelic research, policy and business
   Interviews with insiders
   Monthly interactive database and commentary on psychedelic patents
   Quick-take analysis of major developments
   A Library of primers and explainers
   Access to our full back catalogue


Learn more about Pα+